Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery
Abstract
:1. Introduction
2. Results
2.1. Patients’ Characteristics
2.2. Association of Baseline CBC Ratios on Patients’ Outcomes in the PDS and IDS Groups
2.3. Post-Treatment CBC Ratios
3. Discussion
4. Materials and Methods
4.1. Study Design
4.2. Endpoints
4.3. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24, vi24–vi32. [Google Scholar] [CrossRef] [PubMed]
- Dalmartello, M.; La Vecchia, C.; Bertuccio, P.; Boffetta, P.; Levi, F.; Negri, E.; Malvezzi, M. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann. Oncol. 2022, 33, 330–339. [Google Scholar] [CrossRef] [PubMed]
- Konstantinopoulos, P.A.; Waggoner, S.; Vidal, G.A.; Mita, M.; Moroney, J.W.; Holloway, R.; Van Le, L.; Sachdev, J.C.; Chapman-Davis, E.; Colon-Otero, G.; et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019, 5, 1141–1149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Drew, Y.; Kaufman, B.; Banerjee, S.; Lortholary, A.; Hong, S.H.; Park, Y.H.; Zimmermann, S.; Roxburgh, P.; Ferguson, M.; Alvarez, R.H.; et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann. Oncol. 2019, 30, V485–V486. [Google Scholar] [CrossRef]
- Randall, L.M.; O’Malley, D.M.; Monk, B.J.; Coleman, R.L.; Gaillard, S.; Adams, S.; Duska, L.; Cappucini, F.; Dalton, H.; Holloway, R.W.; et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). J. Clin. Oncol. 2022, 40 (Suppl. S16), 5573. [Google Scholar] [CrossRef]
- Monk, B.J.; Colombo, N.; Oza, A.M.; Fujiwara, K.; Birrer, M.J.; Randall, L.; Poddubskaya, E.V.; Scambia, G.; Shparyk, Y.V.; Lim, M.C.; et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): An open-label, randomised, phase 3 trial. Lancet Oncol. 2021, 22, 1275–1289. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Fujiwara, K.; Ledermann, J.A.; Oza, A.M.; Kristeleit, R.; Ray-Coquard, I.L.; Richardson, G.E.; Sessa, C.; Yonemori, K.; Banerjee, S.; et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021, 22, 1034–1046. [Google Scholar] [CrossRef]
- Moore, K.N.; Bookman, M.; Sehouli, J.; Miller, A.; Anderson, C.; Scambia, G.; Myers, T.; Taskiran, C.; Robison, K.; Mäenpää, J.; et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J. Clin. Oncol. 2021, 39, 1842–1855. [Google Scholar] [CrossRef]
- Winter, W.E., 3rd; Maxwell, G.L.; Tian, C.; Carlson, J.W.; Ozols, R.F.; Rose, P.G.; Markman, M.; Armstrong, D.K.; Muggia, F.; McGuire, W.P. Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2007, 25, 3621–3627. [Google Scholar] [CrossRef]
- Bristow, R.E.; Puri, I.; Chi, D.S. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol. Oncol. 2009, 112, 265–274. [Google Scholar] [CrossRef] [PubMed]
- Vergote, I.; González-Martín, A.; Ray-Coquard, I.; Harter, P.; Colombo, N.; Pujol, P.; Lorusso, D.; Mirza, M.R.; Brasiuniene, B.; Mady, R.; et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann. Oncol. 2022, 33, 276–287. [Google Scholar] [CrossRef] [PubMed]
- Holschneider, C.H.; Berek, J.S. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 2000, 19, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Yu, W.; Ye, Z.; Fang, X.; Jiang, X.; Jiang, Y. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer. J. Ovarian Res. 2019, 12, 88. [Google Scholar] [CrossRef]
- Liu, Y.; Chen, S.; Zheng, C.; Ding, M.; Zhang, L.; Wang, L.; Xie, M.; Zhou, J. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer 2017, 17, 285. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Jiao, X.; Yuan, Z.; Qiu, H.; Guo, R. C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis. Medicine 2017, 96, e7822. [Google Scholar] [CrossRef]
- Chen, G.; Zhu, L.; Yang, Y.; Long, Y.; Li, X.; Wang, Y. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis. Technol. Cancer Res. Treat. 2018, 17, 1533033818791500. [Google Scholar] [CrossRef]
- Yang, Z.; Gu, J.H.; Guo, C.S.; Li, X.H.; Yang, W.C. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: A systematic review and meta-analysis of observational studies. Oncotarget 2017, 8, 46414–46424. [Google Scholar] [CrossRef] [Green Version]
- Huang, Q.T.; Zhou, L.; Zeng, W.J.; Ma, Q.Q.; Wang, W.; Zhong, M.; Yu, Y.H. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cell. Physiol. Biochem. 2017, 41, 2411–2418. [Google Scholar] [CrossRef] [PubMed]
- Yin, X.; Wu, L.; Yang, H.; Yang, H. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Medicine 2019, 98, e17475. [Google Scholar] [CrossRef]
- Eo, W.K.; Chang, H.J.; Kwon, S.H.; Koh, S.B.; Kim, Y.O.; Ji, Y.I.; Kim, H.B.; Lee, J.Y.; Suh, D.S.; Kim, K.H.; et al. The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer. J. Cancer 2016, 7, 289–296. [Google Scholar] [CrossRef] [Green Version]
- Lu, C.; Zhou, L.; Ouyang, J.; Yang, H. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: A meta-analysis. Medicine 2019, 98, e15876. [Google Scholar] [CrossRef] [PubMed]
- Cai, L.; Song, Y.; Zhao, X. Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer. Medicine 2020, 99, e19638. [Google Scholar] [CrossRef]
- Gao, X.P.; Liu, Y.H.; Liu, Z.Y.; Wang, L.J.; Jing, C.X.; Zhu, S.; Zeng, F.F. Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: A meta-analysis. Cancer Manag. Res. 2019, 11, 1907–1920. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gong, J.; Jiang, H.; Shu, C.; Hu, M.Q.; Huang, Y.; Liu, Q.; Li, R.F. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: A meta-analysis. J. Ovarian Res. 2019, 12, 51. [Google Scholar] [CrossRef]
- Prodromidou, A.; Andreakos, P.; Kazakos, C.; Vlachos, D.E.; Perrea, D.; Pergialiotis, V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflamm. Res. 2017, 66, 467–475. [Google Scholar] [CrossRef]
- Zhao, Z.; Zhao, X.; Lu, J.; Xue, J.; Liu, P.; Mao, H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: A meta-analysis of retrospective studies. Arch. Gynecol. Obstet. 2018, 297, 849–857. [Google Scholar] [CrossRef]
- Minici, R.; Siciliano, M.A.; Ammendola, M.; Santoro, R.C.; Barbieri, V.; Ranieri, G.; Laganà, D. Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers 2022, 15, 257. [Google Scholar]
- Allenet, C.; Klein, C.; Rouget, B.; Margue, G.; Capon, G.; Alezra, E.; Blanc, P.; Estrade, V.; Bladou, F.; Robert, G.; et al. Can Pre-Operative Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Non-Metastatic Renal Carcinoma Recurrence after Nephrectomy? (UroCCR-61 Study). Cancers 2022, 14, 5692. [Google Scholar] [CrossRef]
- Farolfi, A.; Petrone, M.; Scarpi, E.; Gallà, V.; Greco, F.; Casanova, C.; Longo, L.; Cormio, G.; Orditura, M.; Bologna, A.; et al. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Target. Oncol. 2018, 13, 469–479. [Google Scholar] [CrossRef]
- Badora-Rybicka, A.; Nowara, E.; Starzyczny-Słota, D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open 2016, 1, e000039. [Google Scholar] [CrossRef] [PubMed]
- Williams, K.A.; Labidi-Galy, S.I.; Terry, K.L.; Vitonis, A.F.; Welch, W.R.; Goodman, A.; Cramer, D.W. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol. Oncol. 2014, 132, 542–550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salman, L.; Sabah, G.; Jakobson-Setton, A.; Raban, O.; Yeoshoua, E.; Eitan, R. Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Int. J. Gynaecol. Obstet. 2020, 148, 102–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asher, V.; Lee, J.; Innamaa, A.; Bali, A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin. Transl. Oncol. 2011, 13, 499–503. [Google Scholar] [CrossRef]
- Li, Z.; Hong, N.; Robertson, M.; Wang, C.; Jiang, G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Sci. Rep. 2017, 7, 43001. [Google Scholar] [CrossRef] [Green Version]
- El Bairi, K.; Al Jarroudi, O.; Afqir, S. Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. Front. Oncol. 2021, 11, 694821. [Google Scholar] [CrossRef]
- Templeton, A.J.; McNamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106, dju124. [Google Scholar] [CrossRef] [Green Version]
- Vergote, I.; Tropé, C.G.; Amant, F.; Kristensen, G.B.; Ehlen, T.; Johnson, N.; Verheijen, R.H.; van der Burg, M.E.; Lacave, A.J.; Panici, P.B.; et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010, 363, 943–953. [Google Scholar] [CrossRef] [Green Version]
- Kehoe, S.; Hook, J.; Nankivell, M.; Jayson, G.C.; Kitchener, H.; Lopes, T.; Luesley, D.; Perren, T.; Bannoo, S.; Mascarenhas, M.; et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 2015, 386, 249–257. [Google Scholar] [CrossRef] [PubMed]
- Wright, A.A.; Bohlke, K.; Armstrong, D.K.; Bookman, M.A.; Cliby, W.A.; Coleman, R.L.; Dizon, D.S.; Kash, J.J.; Meyer, L.A.; Moore, K.N.; et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol. Oncol. 2016, 143, 3–15. [Google Scholar] [CrossRef] [Green Version]
- van Meurs, H.S.; Tajik, P.; Hof, M.H.; Vergote, I.; Kenter, G.G.; Mol, B.W.; Buist, M.R.; Bossuyt, P.M. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur. J. Cancer 2013, 49, 3191–3201. [Google Scholar] [CrossRef] [PubMed]
- Leary, A.; Cowan, R.; Chi, D.; Kehoe, S.; Nankivell, M. Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues. Am. Soc. Clin. Oncol. Educ. Book 2016, 35, 153–162. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.I.; Cassella, C.R.; Byrne, K.T. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front. Immunol. 2021, 11, 629722. [Google Scholar] [CrossRef]
- Worzfeld, T.; Pogge von Strandmann, E.; Huber, M.; Adhikary, T.; Wagner, U.; Reinartz, S.; Müller, R. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front. Oncol. 2017, 7, 24. [Google Scholar] [CrossRef] [Green Version]
- Kandalaft, L.E.; Dangaj Laniti, D.; Coukos, G. Immunobiology of high-grade serous ovarian cancer: Lessons for clinical translation. Nat. Rev. Cancer. 2022, 22, 640–656. [Google Scholar] [CrossRef]
- Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203–213. [Google Scholar] [CrossRef] [Green Version]
- Furumaya, C.; Martinez-Sanz, P.; Bouti, P.; Kuijpers, T.W.; Matlung, H.L. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. Front. Immunol. 2020, 11, 2100. [Google Scholar] [CrossRef]
- Pittet, M.J.; Michielin, O.; Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 2022, 19, 402–421. [Google Scholar] [CrossRef]
- Liu, R.; Hu, R.; Zeng, Y.; Zhang, W.; Zhou, H.H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. EBioMedicine 2020, 51, 102602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brandau, S.; Dumitru, C.A.; Lang, S. Protumor and antitumor functions of neutrophil granulocytes. Semin. Immunopathol. 2013, 35, 163–176. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.; Fu, S.; Mastio, J.; Dominguez, G.A.; Purohit, A.; Kossenkov, A.; Lin, C.; Alicea-Torres, K.; Sehgal, M.; Nefedova, Y.; et al. Unique pattern of neutrophil migration and function during tumor progression. Nat. Immunol. 2018, 19, 1236–1247. [Google Scholar] [CrossRef] [PubMed]
- Sagiv, J.Y.; Michaeli, J.; Assi, S.; Mishalian, I.; Kisos, H.; Levy, L.; Damti, P.; Lumbroso, D.; Polyansky, L.; Sionov, R.V.; et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell. Rep. 2015, 10, 562–573. [Google Scholar] [CrossRef] [Green Version]
- Tazzyman, S.; Lewis, C.E.; Murdoch, C. Neutrophils: Key mediators of tumour angiogenesis. Int. J. Exp. Pathol. 2009, 90, 222–231. [Google Scholar] [CrossRef]
- Labelle, M.; Begum, S.; Hynes, R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011, 20, 576–590. [Google Scholar] [CrossRef] [Green Version]
- Buergy, D.; Wenz, F.; Groden, C.; Brockmann, M.A. Tumor-platelet interaction in solid tumors. Int. J. Cancer. 2012, 130, 2747–2760. [Google Scholar] [CrossRef]
- Feng, Y.; Wang, Z.; Cui, R.; Xiao, M.; Gao, H.; Bai, H.; Delvoux, B.; Zhang, Z.; Dekker, A.; Romano, A.; et al. Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes. J. Ovarian Res. 2022, 15, 64. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Cropet, C.; Van Glabbeke, M.; Sebban, C.; Le Cesne, A.; Judson, I.; Tredan, O.; Verweij, J.; Biron, P.; Labidi, I.; et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009, 69, 5383–5391. [Google Scholar] [CrossRef] [Green Version]
- Cupp, M.A.; Cariolou, M.; Tzoulaki, I.; Aune, D.; Evangelou, E.; Berlanga-Taylor, A.J. Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020, 18, 360. [Google Scholar] [CrossRef]
- He, B.; Wu, J. Clinical Value of PLR, MLR, and NWR in Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Comput. Math. Methods Med. 2022, 2022, 8005975. [Google Scholar] [CrossRef]
- Cong, R.; Kong, F.; Ma, J.; Li, Q.; Wu, Q.; Ma, X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: A superior prognostic factor of endometrial cancer. BMC Cancer 2020, 20, 464. [Google Scholar] [CrossRef] [PubMed]
- Ménétrier-Caux, C.; Ray-Coquard, I.; Blay, J.Y.; Caux, C. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: An opportunity for combination with Cytokines? J. Immunother. Cancer 2019, 7, 85. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, C.; Jiang, X.; Li, Y.; Pan, X.; Gao, M.; Chen, Y.; Pang, B. Independent predictive value of blood inflammatory composite markers in ovarian cancer: Recent clinical evidence and perspective focusing on NLR and PLR. J. Ovarian Res. 2023, 16, 36. [Google Scholar] [CrossRef] [PubMed]
- Marchetti, C.; D’Indinosante, M.; Bottoni, C.; Di Ilio, C.; Di Berardino, S.; Costantini, B.; Minucci, A.; Vertechy, L.; Scambia, G.; Fagotti, A. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci. Rep. 2021, 11, 11125. [Google Scholar] [CrossRef]
- Nguyen, J.M.V.; Ferguson, S.E.; Bernardini, M.Q.; May, T.; Laframboise, S.; Hogen, L.; Bouchard-Fortier, G. Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer. Int. J. Gynecol. Cancer 2020, 30, 1378–1383. [Google Scholar] [CrossRef]
- Kim, Y.J.; Lee, I.; Chung, Y.S.; Nam, E.; Kim, S.; Kim, S.W.; Kim, Y.T.; Lee, J.Y. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet. Gynecol. Sci. 2018, 61, 227–234. [Google Scholar] [CrossRef]
- Liontos, M.; Andrikopoulou, A.; Koutsoukos, K.; Markellos, C.; Skafida, E.; Fiste, O.; Kaparelou, M.; Thomakos, N.; Haidopoulos, D.; Rodolakis, A.; et al. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. J. Ovarian Res. 2021, 14, 148. [Google Scholar] [CrossRef]
- Sanna, E.; Tanca, L.; Cherchi, C.; Gramignano, G.; Oppi, S.; Chiai, M.G.; Macciò, A.; Madeddu, C. Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. Diagnostics 2021, 11, 1298. [Google Scholar] [CrossRef]
- Nantasupha, C.; Muangmool, T.; Charoenkwan, K. Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy. Asian Pac. J. Cancer Prev. 2022, 23, 3791–3799. [Google Scholar] [CrossRef]
- Miao, Y.; Yan, Q.; Li, S.; Li, B.; Feng, Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark. 2016, 17, 33–40. [Google Scholar] [CrossRef]
- Farolfi, A.; Scarpi, E.; Greco, F.; Bergamini, A.; Longo, L.; Pignata, S.; Casanova, C.; Cormio, G.; Bologna, A.; Orditura, M.; et al. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: A MITO24 retrospective study. Sci. Rep. 2020, 10, 18190. [Google Scholar] [CrossRef]
- Fukuda, T.; Kawanishi, M.; Awazu, Y.; Nanno, S.; Shimomura, M.; Inoue, Y.; Matsubara, H.; Yamauchi, M.; Kasai, M.; Hashiguchi, Y.; et al. Neutrophil-to-lymphocyte ratio is associated with sensitivity to platinum-based chemotherapy and prognosis in patients with advanced serous ovarian carcinoma. Mol. Clin. Oncol. 2021, 15, 217. [Google Scholar] [CrossRef]
- Nakanishi, K.; Yamada, T.; Ishikawa, G.; Suzuki, S. Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. Front. Oncol. 2021, 11, 697952. [Google Scholar] [CrossRef]
- Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D.W.; Adusumilli, P.S.; Paik, P.K.; Plitas, G.; Ladanyi, M.; Postow, M.A.; et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 2021, 12, 729. [Google Scholar] [CrossRef] [PubMed]
- Boland, J.L.; Zhou, Q.; Martin, M.; Callahan, M.K.; Konner, J.; O’Cearbhaill, R.E.; Friedman, C.F.; Tew, W.; Makker, V.; Grisham, R.N.; et al. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecol. Oncol. 2019, 152, 251–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanaka, R.; Kimura, K.; Eguchi, S.; Tauchi, J.; Shibutani, M.; Shinkawa, H.; Ohira, G.O.; Yamazoe, S.; Tanaka, S.; Amano, R.; et al. Preoperative Neutrophil-to-lymphocyte Ratio Predicts Tumor-infiltrating CD8+ T Cells in Biliary Tract Cancer. Anticancer. Res. 2020, 40, 2881–2887. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.H.; Kim, E.Y.; Yun, J.S.; Park, Y.L.; Do, S.I.; Chae, S.W.; Park, C.H. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer 2018, 18, 938. [Google Scholar] [CrossRef]
- Hamanishi, J.; Mandai, M.; Konishi, I. Immune checkpoint inhibition in ovarian cancer. Int. Immunol. 2016, 28, 339–348. [Google Scholar] [CrossRef] [Green Version]
- Odunsi, K. Immunotherapy in ovarian cancer. Ann. Oncol. 2017, 28 (Suppl. S8), viii1–viii7. [Google Scholar] [CrossRef]
- Hamanishi, J.; Mandai, M.; Abiko, K.; Matsumura, N.; Baba, T.; Yoshioka, Y.; Kosaka, K.; Konishi, I. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin. Immunol. 2011, 141, 338–347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Common Terminology Criteria for Adverse Events (CTCAE), Version 5; US Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Bethesda, MD, USA, 2017.
Clinical–Pathological Characteristics (n,%) | Total N = 146 | Interval Debulking Surgery N = 85 (58.2%) | Primary Debulking Surgery N = 61 (41.8%) | p-Value |
---|---|---|---|---|
Age: median [IQR] | 62.0 [55.2; 70.0] | 65.0 [58.0; 73.0] | 58.0 [51.0; 65.0] | 0.001 |
≤59 years | 57 (39) | 23 (27.1) | 34 (55.7) | |
>59 years | 89 (61) | 62 (72.9) | 27 (44.3) | |
Histologic subtype | 0.003 | |||
High-grade serous | 124 (84.9) | 79 (92.9) | 45 (73.8) | |
Others | 22 (15.1) | 6 (7.1) | 16 (26.2) | |
BRCA ½ status | 0.414 | |||
Mutated | 30 (20.5) | 15 (17.6) | 15 (24.6) | |
Wild type/Un-known | 116 (79.5) | 70 (82.4) | 46 (75.4) | |
FIGO Stage | 0.118 | |||
III | 101 (69.2) | 54 (63.5) | 47 (77.0) | |
IV | 45 (30.8) | 31 (36.5) | 14 (23) | |
Residual disease | 0.872 | |||
R0 | 117 (80.1) | 69 (81.2) | 48 (78.7) | |
R1/R2 | 29 (19.9) | 16 (18.8) | 13 (21.3) | |
CA-125 (U/mL): median [IQR] | 714.4 [262.6; 1756.0] | 970.0 [410.8; 2082.2] | 436.8 [147.0; 1331.7] | 0.011 * |
Neutrophil (×103/µL): median [IQR] | 5.15 [4.0; 6.5] | 5.2 [4.1; 6.6] | 4.8 [3.8; 6] | 0.165 * |
Monocyte(×103/µL): median [IQR] | 0.6 [0.5; 0.7] | 0.6 [0.5; 0.8] | 0.6 [0.5; 0.6] | 0.046 * |
Platelet (×103/µL): median [IQR] | 328 [265.5; 425.5] | 367 [279; 468] | 303 [253; 361] | 0.003 * |
Lymphocyte (×103/µL): median [IQR] | 1.35 [1.1; 1.8] | 1.2 [1.0; 1.6] | 1.57 [1.2; 2] | 0.004 * |
NLR: median [IQR] | 3.8 [2.4; 5.3] | 4.3 [2.9; 6.4] | 3.1 [1.9; 4.7] | 0.004 |
MLR: median [IQR] | 0.4 [0.3; 0.6] | 0.4 [0.3; 0.7] | 0.4 [0.2; 0.5] | 0.009 |
PLR: median [IQR] | 258.6 [154.2; 391.1] | 315.0 [193.2; 436.4] | 193.1 [140.7; 300.0] | 0.001 |
Median OS: months (95% CI) | 50.15 (42.2–81.7) | 39.8 (33.8–49.3) | 86.4 (72.7–NR) | 0.0001 |
Median PFS: months (95% CI) | 18.86 (16.8–22.5) | 16.4 (14.8–19.2) | 30.7 (22–40.8) | 0.0004 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Plaja, A.; Teruel, I.; Ochoa-de-Olza, M.; Cucurull, M.; Arroyo, Á.J.; Pardo, B.; Ortiz, I.; Gil-Martin, M.; Piulats, J.M.; Pla, H.; et al. Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery. Int. J. Mol. Sci. 2023, 24, 11420. https://doi.org/10.3390/ijms241411420
Plaja A, Teruel I, Ochoa-de-Olza M, Cucurull M, Arroyo ÁJ, Pardo B, Ortiz I, Gil-Martin M, Piulats JM, Pla H, et al. Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery. International Journal of Molecular Sciences. 2023; 24(14):11420. https://doi.org/10.3390/ijms241411420
Chicago/Turabian StylePlaja, Andrea, Iris Teruel, Maria Ochoa-de-Olza, Marc Cucurull, Álvaro Javier Arroyo, Beatriz Pardo, Irene Ortiz, Marta Gil-Martin, Josep María Piulats, Helena Pla, and et al. 2023. "Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery" International Journal of Molecular Sciences 24, no. 14: 11420. https://doi.org/10.3390/ijms241411420